Z
7.20
0.00 (-0.07%)
| Previous Close | 7.20 |
| Open | 7.25 |
| Volume | 83,576 |
| Avg. Volume (3M) | 464,485 |
| Market Cap | 393,418,304 |
| Price / Sales | 14.10 |
| Price / Book | 9.93 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2025 - 9 May 2025 |
| Operating Margin (TTM) | -128.01% |
| Diluted EPS (TTM) | -2.28 |
| Quarterly Revenue Growth (YOY) | -6.80% |
| Total Debt/Equity (MRQ) | 152.01% |
| Current Ratio (MRQ) | 2.53 |
| Operating Cash Flow (TTM) | -69.67 M |
| Levered Free Cash Flow (TTM) | -36.36 M |
| Return on Assets (TTM) | -31.03% |
| Return on Equity (TTM) | -207.84% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Zevra Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
1.0
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | -2.0 |
| Average | 1.00 |
|
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.62% |
| % Held by Institutions | 62.37% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Aigh Capital Management Llc | 31 Dec 2024 | 788,614 |
| Stonepine Capital Management, Llc | 31 Dec 2024 | 597,700 |
| Retirement Planning Co Of New England, Inc. | 31 Dec 2024 | 514,832 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 25.00 (Canaccord Genuity, 247.46%) | Buy |
| 25.00 (Cantor Fitzgerald, 247.46%) | Buy | |
| Median | 22.00 (205.77%) | |
| Low | 18.00 (Citizens Capital Markets, 150.17%) | Buy |
| Average | 22.00 (205.77%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 7.93 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 13 Mar 2025 | 25.00 (247.46%) | Buy | 7.94 |
| Guggenheim | 13 Mar 2025 | 22.00 (205.77%) | Buy | 7.94 |
| HC Wainwright & Co. | 13 Mar 2025 | 20.00 (177.97%) | Buy | 7.94 |
| Cantor Fitzgerald | 12 Mar 2025 | 25.00 (247.46%) | Buy | 7.92 |
| Citizens Capital Markets | 12 Mar 2025 | 18.00 (150.17%) | Buy | 7.92 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |